Gita Suneja, MD, MS, physician-scientist at Huntsman Cancer Institute and professor of radiation oncology at the U, is the first author of the SAVE trial report—which stands for Short-Course Adjuvant ...

SAN DIEGO, October 1, 2023 — In a first-of-its-kind study, people with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, ...

18F-DOPA PET-guided proton beam therapy improved overall survival in older glioblastoma patients, with a median OS of 13.1 months and no grade 4 adverse events. The hypofractionated regimen, completed ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...

It used to be that radiation therapy for prostate cancer involved weeks or months of repeat visits to a clinic for treatment. Today that's not necessarily true. Instead of giving small doses (called ...

The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data. This is an ...

Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...

Radiation therapy for vulvar cancer uses high energy waves to kill cancer cells. It may help shrink a tumor so a doctor can surgically remove it, and it may help kill any cancer cells that remain ...

Please provide your email address to receive an email when new articles are posted on . A meta-analysis of 29 prospective studies showed a 44% reduction in risk for short-term urinary adverse events.

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable ...